Nyxoah SA reports medical-technology developments tied to the Genio system, its patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for obstructive sleep apnea. Company news commonly covers financial and operating results, U.S. commercialization activity, regulatory status, manufacturing capacity, reimbursement references, investor conference participation, and the development and commercialization of OSA treatment alternatives.
Nyxoah also publishes regulated information for its Euronext Brussels and Nasdaq securities, including transparency notifications, shareholder-meeting materials, voting-right disclosures, and bond-related capital-structure notices.
Nyxoah (Nasdaq: NYXH) announced $110 million in aggregate financings to support the U.S. commercial launch of its Genio system for obstructive sleep apnea.
The company completed a $95 million equity financing and expects a $15 million second tranche from its European Investment Bank loan by end of June 2026, backing an accelerated U.S. commercialization with 40 sales reps already in place.
Nyxoah (Nasdaq: NYXH) closed an underwritten public offering of 55,232,558 ordinary shares at $1.72 (EUR 1.48) per share, raising approximately $95.0 million (EUR 81.9 million) in gross proceeds.
Nyxoah plans to fund U.S. commercialization, Genio system R&D and cost reductions, international launches, clinical data generation, and general corporate purposes. It also intends to draw EUR 13.8 million from the second tranche of its European Investment Bank loan in Q2 2026.
Nyxoah (NASDAQ:NYXH) priced a $95 million underwritten public offering of 55,232,558 ordinary shares at $1.72 (EUR 1.48) per share, with no selling shareholders and a 30‑day option for 8,284,883 additional shares.
Closing is expected around June 9, 2026. According to Nyxoah, net proceeds will fund U.S. commercialization, Genio system R&D and upgrades, international commercialization and clinical data generation, and general corporate purposes. The company also plans to draw EUR 13.8 million from the second tranche of its European Investment Bank loan in Q2 2026.
Nyxoah (Nasdaq: NYXH) launched a proposed underwritten public offering of ordinary shares in the United States, with no selling shareholders participating.
The company may grant underwriters a 30-day option for up to 15% additional shares and plans to use proceeds for U.S. and international commercialization of the Genio system, R&D, clinical data generation, and general corporate purposes.
Nyxoah (Nasdaq: NYXH) announced a leadership transition process aimed at accelerating long-term value creation and U.S. commercial growth for its Genio system for Obstructive Sleep Apnea.
The Board has launched a search for a new U.S.-based CEO, while current CEO Olivier Taelman will remain fully engaged and lead daily operations during the transition.
Nyxoah (Nasdaq: NYXH) reported updated capital and voting rights on May 20, 2026, following the issuance of 1,031,323 new shares via a contribution in kind of a receivable linked to its convertible bonds.
Share capital is now EUR 6,521,361.42 with 44,693,726 shares and voting rights outstanding, plus detailed disclosure of subscription rights and convertible bond conversion scenarios.
Nyxoah (Nasdaq:Euronext Brussels: NYXH) hosted the Flemish Investors Federation (VFB) at LégiaPark in Liège following its Q1 2026 results and growing U.S. commercial activity.
Management highlighted U.S. Genio® system commercialization after FDA approval in August 2025 and its new LégiaPark manufacturing investment.
Nyxoah (Nasdaq:Euronext: NYXH) reported Q1 2026 net revenue of €6.4 million, up from €1.1 million a year earlier. U.S. net revenue reached €4.3 million, a 25% sequential increase, with global net revenue up 13% sequentially.
Gross margin was 57%. Operating loss was €20.5 million. Cash and financial assets totaled €25.9 million, with a planned €13.8 million EIB loan draw in Q2. 2026 guidance includes €36–40 million global net revenue, 60–62% gross margin and €97–99 million operating expenses.
NYXOAH (NASDAQ: NYXH) invites shareholders to the annual and extraordinary meetings on June 10, 2026 at 14:00 CET, with a video conference facility for registered holders. Registration date is May 27, 2026; remote voting or proxy required to vote.
The agenda includes approval of 2025 statutory and consolidated accounts, ratification of bond terms for the EUR 22,500,000 convertible bonds issued December 18, 2025, renewal of authorized capital for five years, multiple director reappointments/appointments, and related corporate formalities.
Nyxoah (NASDAQ: NYXH) will present at the Bank of America 2026 Healthcare Conference on Wednesday, May 13, 2026. The presentation is scheduled for 5:15 PM ET and will be available via live audio webcast. The company will hold 1x1 meetings with institutional investors attending the event.